Xencor, Inc. (XNCR)
XNCR Stock Price Chart
Explore Xencor, Inc. interactive price chart. Choose custom timeframes to analyze XNCR price movements and trends.
XNCR Company Profile
Discover essential business fundamentals and corporate details for Xencor, Inc. (XNCR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Dec 2013
Employees
250.00
Website
https://www.xencor.comCEO
Bassil I. Dahiyat
Description
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
XNCR Financial Timeline
Browse a chronological timeline of Xencor, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.84, while revenue estimate is $18.22m.
Earnings released on 6 May 2026
EPS came in at -$1.71 falling short of the estimated -$0.65 by -163.08%, while revenue for the quarter reached $4.52m , missing expectations by -83.79%.
Earnings released on 25 Feb 2026
EPS came in at -$0.09 surpassing the estimated -$0.64 by +85.94%, while revenue for the quarter reached $28.24m , missing expectations by -5.76%.
Earnings released on 5 Nov 2025
EPS came in at -$0.08 surpassing the estimated -$0.72 by +88.89%, while revenue for the quarter reached $21.00m , missing expectations by -29.92%.
Earnings released on 6 Aug 2025
EPS came in at -$0.41 surpassing the estimated -$0.78 by +47.44%, while revenue for the quarter reached $43.61m , beating expectations by +78.94%.
Earnings released on 7 May 2025
EPS came in at -$0.66 falling short of the estimated -$0.63 by -4.76%, while revenue for the quarter reached $32.73m , beating expectations by +45.54%.
Earnings released on 27 Feb 2025
EPS came in at -$0.62 surpassing the estimated -$0.81 by +23.46%, while revenue for the quarter reached $70.02m , beating expectations by +313.33%.
Earnings released on 6 Nov 2024
EPS came in at -$0.71 surpassing the estimated -$0.98 by +27.55%, while revenue for the quarter reached $10.71m , missing expectations by -35.56%.
Earnings released on 5 Aug 2024
EPS came in at -$1.07 falling short of the estimated -$0.85 by -25.88%, while revenue for the quarter reached $16.96m , beating expectations by +7.14%.
Earnings released on 9 May 2024
EPS came in at -$1.11 falling short of the estimated -$0.76 by -46.05%, while revenue for the quarter reached $12.81m , missing expectations by -48.76%.
Earnings released on 27 Feb 2024
EPS came in at -$0.31 falling short of the estimated $0.36 by -186.11%, while revenue for the quarter reached $44.69m , missing expectations by -39.48%.
Earnings released on 7 Nov 2023
EPS came in at -$0.40 surpassing the estimated -$0.77 by +48.05%, while revenue for the quarter reached $59.16m , beating expectations by +101.79%.
Earnings released on 3 Aug 2023
EPS came in at -$0.37 surpassing the estimated -$0.91 by +59.34%, while revenue for the quarter reached $45.52m , beating expectations by +57.03%.
Earnings released on 8 May 2023
EPS came in at -$1.02 falling short of the estimated -$0.75 by -36.00%, while revenue for the quarter reached $18.96m , missing expectations by -32.21%.
Earnings released on 23 Feb 2023
EPS came in at -$0.20 surpassing the estimated -$0.83 by +75.90%, while revenue for the quarter reached $21.61m , beating expectations by +7.68%.
Earnings released on 7 Nov 2022
EPS came in at -$0.55 surpassing the estimated -$0.77 by +28.57%, while revenue for the quarter reached $27.30m , beating expectations by +29.68%.
Earnings released on 3 Aug 2022
EPS came in at -$0.57 falling short of the estimated -$0.45 by -26.67%, while revenue for the quarter reached $30.18m , missing expectations by -11.28%.
Earnings released on 5 May 2022
EPS came in at $0.39 surpassing the estimated -$0.61 by +163.93%, while revenue for the quarter reached $85.50m , beating expectations by +227.04%.
Earnings released on 23 Feb 2022
EPS came in at $1.21 surpassing the estimated -$0.10 by +1.31k%, while revenue for the quarter reached $154.02m , beating expectations by +101.88%.
Earnings released on 8 Nov 2021
EPS came in at -$0.69 surpassing the estimated -$0.75 by +8.00%, while revenue for the quarter reached $19.68m , missing expectations by -7.76%.
Earnings released on 4 Aug 2021
EPS came in at $0.87 surpassing the estimated -$0.56 by +255.36%, while revenue for the quarter reached $67.45m , beating expectations by +243.94%.
XNCR Stock Performance
Access detailed XNCR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
